Observational Study
Copyright ©The Author(s) 2024.
World J Psychiatry. Oct 19, 2024; 14(10): 1467-1473
Published online Oct 19, 2024. doi: 10.5498/wjp.v14.i10.1467
Table 1 Baseline characteristics of the study population stratified by the presence or absence of cognitive impairment, anxiety, and depressive symptoms
Characteristic
Cognitive impairment
P value
Anxiety
P value
Depressive symptoms
P value
Yes (n = 52)
No (n = 98)
Yes (n = 42)
No (n = 108)
Yes (n = 48)
No (n = 102)
Age, year, mean ± SD68.3 ± 9.563.8 ± 10.30.01066.9 ± 9.864.8 ± 10.30.26167.5 ± 9.664.4 ± 10.30.083
Male, n (%)28 (53.8)59 (60.2)0.44822 (52.4)65 (60.2)0.37925 (52.1)62 (60.8)0.312
BMI, kg/m2, mean ± SD24.8 ± 3.224.3 ± 3.10.35624.5 ± 3.324.5 ± 3.10.98024.6 ± 3.224.4 ± 3.10.720
Smoking, n (%)18 (34.6)30 (30.6)0.61415 (35.7)33 (30.6)0.54017 (35.4)31 (30.4)0.534
Hypertension, n (%)37 (71.2)61 (62.2)0.27329 (69.0)69 (63.9)0.54833 (68.8)65 (63.7)0.544
Diabetes, n (%)19 (36.5)28 (28.6)0.31115 (35.7)32 (29.6)0.47218 (37.5)29 (28.4)0.262
Dyslipidemia, n (%)28 (53.8)46 (46.9)0.41522 (52.4)52 (48.1)0.63925 (52.1)49 (48.0)0.637
Previous stroke, n (%)10 (19.2)14 (14.3)0.4178 (19.0)16 (14.8)0.5229 (18.8)15 (14.7)0.523
NIHSS score at admission, median (interquartile range)8 (5-12)5 (3-9)0.0017 (4-11)6 (3-9)0.1188 (4-12)5 (3-9)0.007
Table 2 Serum neutrophil gelatinase-associated lipocalin levels at admission in patients with and without cognitive impairment, anxiety, and depressive symptoms
Neuropsychiatric complication
Serum NGAL levels (ng/mL)
P value
Yes
No
Cognitive impairment, median (interquartile range)5.6 (4.2-7.1)3.2 (2.4-4.3)< 0.001
Anxiety, median (interquartile range)5.1 (3.8-6.6)3.5 (2.6-4.7)0.002
Depressive symptoms, median (interquartile range)5.4 (4.0-6.9)3.3 (2.5-4.5)< 0.001
Table 3 Multivariate logistic regression analysis of the association between serum neutrophil gelatinase-associated lipocalin levels and neuropsychiatric comorbidities
Outcome
Odds ratio (95%CI)
P value
Cognitive impairment1.42 (1.18-1.71)< 0.001
Anxiety1.28 (1.09-1.51)0.003
Depressive symptoms1.39 (1.16-1.67)< 0.001
Table 4 Discriminative ability of serum neutrophil gelatinase-associated lipocalin levels for predicting cognitive impairment, anxiety, and depressive symptoms using receiver operating characteristic curve analysis
Neuropsychiatric complication
AUC (95%CI)
Optimal cut-off value (ng/mL)
Sensitivity (%)
Specificity (%)
Cognitive impairment0.78 (0.71-0.85)4.275.070.4
Anxiety0.67 (0.58-0.76)4.066.763.0
Depressive symptoms0.71 (0.63-0.79)4.170.865.7